Provides a comprehensive review of and commercial forecast for later - stage pipeline gene therapies.
This analysis includes:
- Explanation of the scientific and clinical rationale, advantages and disadvantages for gene therapies in cancer
- Overview of the indications and prevalent populations being targeted by later-stage gene therapies
- Clinical trials data, projections for clinical uptake and a summary of drug - and company - specific marketing factors for each agent
- Comparison of gene therapy with traditional cancer therapies and with other novel drug classes
- Explanation of key factors driving sales of agents expected to be commercialized over the next few years
View Cart
